Last $15.10 USD
Change Today +0.06 / 0.40%
Volume 227.2K
DRNA On Other Exchanges
As of 8:10 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

dicerna pharmaceuticals inc (DRNA) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/14 - $46.00
52 Week Low
07/25/14 - $14.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

dicerna pharmaceuticals inc (DRNA) Related Businessweek News

No Related Businessweek News Found

dicerna pharmaceuticals inc (DRNA) Details

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including hemophilia, porphyria, hypercholesterolemia, hemoglobinopathies, alpha-1-antitrypsin deficiency hepatocyte, inclusions, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated, as well as a product candidate targeting the oncogene KRAS; and a second product candidate targeting an oncogene. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of drug delivery platforms and DsiRNA molecules for therapeutic targets, primarily in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.

22 Employees
Last Reported Date: 03/27/14
Founded in 2006

dicerna pharmaceuticals inc (DRNA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $375.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $65.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $315.0K
Chief Business Officer
Total Annual Compensation: $295.0K
Compensation as of Fiscal Year 2013.

dicerna pharmaceuticals inc (DRNA) Key Developments

Watertown Biotech Dicerna Signs Lease for Larger Headquarters in Cambridge

Dicerna Pharmaceuticals, Inc. signed a lease for a 37,200-square-foot office and laboratory space at 87 CambridgePark Drive in Cambridge. The building is the site of the former Pfizer building near Alewife. The six-year lease begins in December, or when the building's owner completes work on the space. The average monthly rent will be $134,000, according to the filing.

Dicerna Pharmaceuticals, Inc. Announces Presentation of Preclinical Data Demonstrating of Preclinical Model of Primary Hyperoxaluria Type 1

Dicerna Pharmaceuticals, Inc. announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1), a rare inherited liver disorder that often results in progressive and severe kidney damage. The research was presented at the 11(th) International Primary Hyperoxaluria Workshop in Chicago by Eduardo Salido, Ph.D., Professor of Pathology at the University of La Laguna in Santa Cruz de Tenerife, Spain. The preclinical studies showed that DCR-PH1 provides potent and long-term inhibition of HAO1, a gene implicated in the pathogenesis of PH1. In a genetically modified mouse model of PH1, researchers reported a 97% reduction of the HAO1 transcript in the liver after a single dose of DCR-PH1 and a significant reduction in urinary oxalate levels, a key marker of the disease. In mice treated with DCR-PH1, urinary oxalate levels returned to near baseline levels, similar to normal mice. PH1 occurs when a liver enzyme called AGT does not function properly due to a genetic defect, inducing the liver to over-produce a metabolite called oxalate. While oxalate has no clinical effect in a healthy population, it is concentrated in the urine by the kidneys of patients with PH1, forming calcium oxalate crystals that can lead to chronic and painful cases of kidney stones, scarring of the kidney and end-stage renal disease. DCR-PH1 is engineered to address the pathology of PH1 by targeting and destroying the messenger RNA (mRNA) produced by HAO1, a gene that encodes glycolate oxidase, a protein involved in producing oxalate. By reducing oxalate production, this approach is designed to prevent the complications of PH1.

Dicerna Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 01:00 PM

Dicerna Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 01:00 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Douglas M. Fambrough, Co-Founder, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRNA:US $15.10 USD +0.06

DRNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DRNA.
View Industry Companies

Industry Analysis


Industry Average

Valuation DRNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DICERNA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at